AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21264786 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated animals
Number of subjects: 0
Study 18669952 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle reconstruction
Number of subjects: 0
Study 18669952 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle reconstruction
Number of subjects: 0
Study 16819563 — intervention group
Group type: EXPERIMENTAL
Intervention: Shouldice repair
Number of subjects: 151
Study 16819563 — intervention group
Group type: COMPARATOR
Intervention: TAPP and Bassini repairs
Number of subjects: 151
Study 15638033 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 5 mg
Number of subjects: 88
Study 15638033 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 88
Study 15638033 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 88
Study 15638033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 10789326 — intervention group
Group type: EXPERIMENTAL
Intervention: Signed reviews
Number of subjects: 408
Study 10789326 — intervention group
Group type: COMPARATOR
Intervention: Unsigned reviews
Number of subjects: 408
Study 9076465 — intervention group
Group type: EXPERIMENTAL
Intervention: SR-alfuzosin 5 mg twice daily
Number of subjects: 390
Study 7690956 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (160 mg/day)
Number of subjects: 23
Study 7690956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 3530572 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevantolol, 150 mg
Number of subjects: 0
Study 3530572 — intervention group
Group type: COMPARATOR
Intervention: Propranolol, 80 mg
Number of subjects: 0
Study 3530572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29168446 — intervention group
Group type: EXPERIMENTAL
Intervention: Gown designed for easy removal at the neck with increased skin coverage and snugness of fit at the wrist
Number of subjects: 0
Study 29168446 — intervention group
Group type: COMPARATOR
Intervention: Standard gown (implied control)
Number of subjects: 0
Study 27018465 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hour wound dressing removal
Number of subjects: 320
Study 27018465 — intervention group
Group type: COMPARATOR
Intervention: 24-hour wound dressing removal
Number of subjects: 320
Study 24902407 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating-rotating power brush (Oral-B Professional Care 1000)
Number of subjects: 131
Study 24902407 — intervention group
Group type: COMPARATOR
Intervention: Sonic power brush (Colgate ProClinical C200)
Number of subjects: 131
Study 22629214 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for ventilator support
Number of subjects: 100
Study 19877824 — intervention group
Group type: EXPERIMENTAL
Intervention: GaAs laser therapy
Number of subjects: 49
Study 19877824 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser therapy
Number of subjects: 49
Study 18394060 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (bicycle ergometer for minimum 30 min at each HD session for 3 months)
Number of subjects: 19
Study 18394060 — intervention group
Group type: COMPARATOR
Intervention: No intradialytic exercise (first 3 months)
Number of subjects: 19
Study 18394060 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of exercise (after 3 months of exercise)
Number of subjects: 19
Study 18394060 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic exercise (after 3 months of no exercise)
Number of subjects: 19
Study 18394060 — intervention group
Group type: COMPARATOR
Intervention: 3 months of exercise vs. 3 months of no exercise
Number of subjects: 19
Study 16152824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgolide nebulised inhalation 10 mg/ml, twice daily, for 6 weeks
Number of subjects: 0
Study 16152824 — intervention group
Group type: COMPARATOR
Intervention: Cromlyn sodium nebulised inhalation 20 mg/10 ml, twice daily, for 6 weeks
Number of subjects: 0
Study 16152824 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 10 ml, twice daily, for 4 weeks
Number of subjects: 0
Study 14610012 — intervention group
Group type: EXPERIMENTAL
Intervention: PV‐LAJ disconnection combined with cavotricuspid isthmus (CTI) ablation (group 1)
Number of subjects: 108
Study 14610012 — intervention group
Group type: COMPARATOR
Intervention: PV‐LAJ disconnection alone (group 2)
Number of subjects: 108
Study 14610012 — intervention group
Group type: EXPERIMENTAL
Intervention: PV‐LAJ disconnection combined with CTI ablation (group 1)
Number of subjects: 108
Study 14610012 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat PV‐LAJ disconnection procedure
Number of subjects: 108
Study 11052317 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy with omeprazole 20 mg once a day for three months
Number of subjects: 40
Study 11052317 — intervention group
Group type: COMPARATOR
Intervention: Placebo with omeprazole 20 mg once a day for three months
Number of subjects: 40
Study 11052317 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-positive dyspeptic patients
Number of subjects: 40
Study 11052317 — intervention group
Group type: EXPERIMENTAL
Intervention: Scintigraphic examination
Number of subjects: 40
Study 8644692 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg elemental Ca/d as calcium citrate malate
Number of subjects: 26
Study 8644692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 1725016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (2.5 or 5 mg twice daily)
Number of subjects: 2000
Study 1725016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study 6339292 — intervention group
Group type: EXPERIMENTAL
Intervention: Halometasone/triclosan cream (0.05% halometasone and 1% triclosan)
Number of subjects: 265
Study 6339292 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate/gentamicin sulphate cream (0.05% betamethasone dipropionate and 0.1% gentamicin sulphate)
Number of subjects: 265
Study 31056413 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-platelet therapy
Number of subjects: 681
Study 31056413 — intervention group
Group type: COMPARATOR
Intervention: No anti-platelet therapy
Number of subjects: 681
Study 30284865 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) distraction
Number of subjects: 39
Study 30284865 — intervention group
Group type: COMPARATOR
Intervention: No VR
Number of subjects: 39
Study 27746557 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia (n = 30)
Number of subjects: 60
Study 27746557 — intervention group
Group type: COMPARATOR
Intervention: ETAG-guided anesthesia (n = 30)
Number of subjects: 60
Study 25220886 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporosis Prevention and Self-Management Course (OPSMC)
Number of subjects: 347
Study 25220886 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback of bone density-defined fracture risk (high vs normal risk)
Number of subjects: 347
Study 25220886 — intervention group
Group type: COMPARATOR
Intervention: Households with unemployed main financial provider
Number of subjects: 347
Study 23114000 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured priority-setting consultation by trained intervention GPs
Number of subjects: 317
Study 23114000 — intervention group
Group type: COMPARATOR
Intervention: Unstructured consultation by untrained control GPs
Number of subjects: 317
Study 20977257 — intervention group
Group type: EXPERIMENTAL
Intervention: Solar disinfection of drinking water (SODIS)
Number of subjects: 718
Study 20977257 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher motivation (75% or better completion of diarrhea data)
Number of subjects: 718
Study 18405377 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental practice-based rehabilitation training (six-week, individually tailored therapy regime)
Number of subjects: 160
Study 18405377 — intervention group
Group type: COMPARATOR
Intervention: Bimanual upper extremity exercises (control group)
Number of subjects: 160
Study 18405377 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental practice-based rehabilitation training
Number of subjects: 160
Study 15845431 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/HCV co-infection
Number of subjects: 1389
Study 15845431 — intervention group
Group type: COMPARATOR
Intervention: HIV alone
Number of subjects: 1389
Study 12211224 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg bid)
Number of subjects: 24
Study 12211224 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (75 mg bid)
Number of subjects: 24
Study 12211224 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg bid) and Diclofenac (75 mg bid)
Number of subjects: 24
Study 10761326 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose oral contraceptive pill (OCs)
Number of subjects: 80
Study 10761326 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 80
Study 10761326 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant
Number of subjects: 80
Study 10761326 — intervention group
Group type: COMPARATOR
Intervention: IUD (Control)
Number of subjects: 80
Study 8797513 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein quartile 4
Number of subjects: 737
Study 8797513 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 737
Study 8797513 — intervention group
Group type: EXPERIMENTAL
Intervention: α1 acid glycoprotein
Number of subjects: 737
Study 1466576 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 gm dipirone plus 20 mg hyoscine N‐butylbromide
Number of subjects: 52
Study 1466576 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg flurbiprofen
Number of subjects: 52
Study 6722830 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 X 10(6) units of partially purified human leukocyte (alpha) interferon by daily im injection for 42 days
Number of subjects: 44
Study 6722830 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 X 10(6) units of partially purified human leukocyte (alpha) interferon by daily im injection for 42 days
Number of subjects: 44
Study 6722830 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 X 10(6) units of partially purified human leukocyte (alpha) interferon by daily im injection for 42 days
Number of subjects: 44
Study 29248654 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CTA+CTP
Number of subjects: 300
Study 29248654 — intervention group
Group type: COMPARATOR
Intervention: Coronary CTA
Number of subjects: 300
Study 27737636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone (24 mcg) + 2 L PEG (GrB)
Number of subjects: 442
Study 27737636 — intervention group
Group type: COMPARATOR
Intervention: Placebo + 2 L PEG (GrA)
Number of subjects: 442
Study 27737636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone (24 mcg) + 1.5 L PEG (GrC)
Number of subjects: 442
Study 27737636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubiprostone (24 mcg) + 1 L PEG (GrD)
Number of subjects: 442
Study 25483700 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine
Number of subjects: 0
Study 25483700 — intervention group
Group type: COMPARATOR
Intervention: HPV-6/11/16/18 vaccine
Number of subjects: 0
Study 23122299 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-flow left ventricular assist device (LVAD) implantation
Number of subjects: 25
Study 23122299 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 25
Study 20400899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 20
Study 20400899 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy
Number of subjects: 20
Study 18584505 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental program (focused review of ITLS and combat casualty care with hands-on procedure training)
Number of subjects: 29
Study 18584505 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as those who did not complete the experimental program)
Number of subjects: 29
Study 16083996 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/2-PN + GH (n=8)
Number of subjects: 35
Study 16083996 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-PN + GH (n=7)
Number of subjects: 35
Study 16083996 — intervention group
Group type: COMPARATOR
Intervention: 1/2-PN (n=11)
Number of subjects: 35
Study 16083996 — intervention group
Group type: COMPARATOR
Intervention: Full-PN (n=9)
Number of subjects: 35
Study 16083996 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 35
Study 12442956 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox-driven bronchodilator (HDBD)
Number of subjects: 31
Study 12442956 — intervention group
Group type: COMPARATOR
Intervention: Air-driven bronchodilator (ADBD)
Number of subjects: 31
Study 11914308 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trials reported in general health care journals
Number of subjects: 5503
Study 11914308 — intervention group
Group type: COMPARATOR
Intervention: Trials with fewer than 100 participants
Number of subjects: 5503
Study 11914308 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials with 100 participants or more
Number of subjects: 5503
Study 9809623 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline and ciprofloxacin (PC) therapy for 12 weeks
Number of subjects: 43
Study 9809623 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline and ciprofloxacin with dexamethasone (PCD) therapy
Number of subjects: 43
Study 9809623 — intervention group
Group type: EXPERIMENTAL
Intervention: PC therapy
Number of subjects: 43
Study 7660408 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric team using a day hospital facility
Number of subjects: 120
Study 7660408 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical management
Number of subjects: 120
Study 1974688 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol MDI (12 micrograms)
Number of subjects: 66
Study 1974688 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol MDI (6, 12, and 24 micrograms)
Number of subjects: 66
Study 1974688 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol MDI (2 X 12 micrograms)
Number of subjects: 66
Study 1974688 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol MDI (2 X 12 micrograms) during 3-month monotherapy
Number of subjects: 66
Study 14658 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg and 2 mg)
Number of subjects: 30
Study 14658 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg and 20 mg)
Number of subjects: 30
Study 14658 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (4 mg)
Number of subjects: 30
Study 14658 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study 7083724 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (15 mg) in supine position (part A)
Number of subjects: 6
Study 7083724 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening dose of midazolam (part C)
Number of subjects: 6
Study 7083724 — intervention group
Group type: COMPARATOR
Intervention: Morning dose of midazolam (part B)
Number of subjects: 6
Study 29942127 — intervention group
Group type: EXPERIMENTAL
Intervention: Breezhaler
Number of subjects: 130
Study 29942127 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuair
Number of subjects: 130
Study 29942127 — intervention group
Group type: EXPERIMENTAL
Intervention: Ellipta
Number of subjects: 130
Study 29942127 — intervention group
Group type: COMPARATOR
Intervention: Demonstration
Number of subjects: 130
Study 26957849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound Biomicroscopy (UBM)
Number of subjects: 10
Study 26957849 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Number of subjects: 10
Study 24245543 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral-valve repair
Number of subjects: 251
Study 24245543 — intervention group
Group type: COMPARATOR
Intervention: Chordal-sparing replacement
Number of subjects: 251
Study 23088447 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer Acetate (GA) exposure
Number of subjects: 423
Study 23088447 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon Beta (IFNB) exposure
Number of subjects: 423
Study 23088447 — intervention group
Group type: COMPARATOR
Intervention: Non-exposed pregnancies (NEP)
Number of subjects: 423
Study 20046179 — intervention group
Group type: EXPERIMENTAL
Intervention: Malarigen Malaria Pf/Pv Antigen Rapid Test (RDT)
Number of subjects: 262
Study 20046179 — intervention group
Group type: COMPARATOR
Intervention: Microscopy (Gold Standard)
Number of subjects: 262
Study 18343245 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin XL 80 mg/d + Ezetimibe 10 mg/d
Number of subjects: 82
Study 18343245 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin XL 80 mg/d
Number of subjects: 82
Study 15860279 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior incision
Number of subjects: 574
Study 15860279 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpendicular relaxing limbal incision
Number of subjects: 574
Study 15860279 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal incision
Number of subjects: 574
Study 15860279 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal incision
Number of subjects: 574
Study 12784090 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone 50 mg monthly injections
Number of subjects: 30
Study 12784090 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone at a weekly dose of 0.7 mg/kg
Number of subjects: 30
Study 12784090 — intervention group
Group type: COMPARATOR
Intervention: Testosterone 25 mg monthly injections
Number of subjects: 30
Study 10573656 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG high dose (0.1 mg/0.1 ml)
Number of subjects: 281161
Study 10573656 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG low dose (0.01 mg/0.1 ml)
Number of subjects: 281161
Study 10573656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281161
Study 8824687 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg orally)
Number of subjects: 10
Study 8824687 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (0.1 mg kg‐1 intravenously)
Number of subjects: 10
Study 8824687 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine + Naloxone (0.8 mg intravenously)
Number of subjects: 10
Study 8824687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2061684 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol and estriol (2:1 ratio), 4 mg/day for 21 days (Group A)
Number of subjects: 18
Study 2061684 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol and estriol (2:1 ratio), 4 mg/day for 28 days (Group B)
Number of subjects: 18
Study 2061684 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol and estriol (2:1 ratio), 4 mg/day for 35 days (Group C)
Number of subjects: 18
Study 6340274 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft irradiation (175 rads every other day, total of 525 rads)
Number of subjects: 64
Study 6340274 — intervention group
Group type: COMPARATOR
Intervention: Standard medical management (intravenous methylprednisolone)
Number of subjects: 64
Study 31587707 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related medical rehabilitation
Number of subjects: 484
Study 31587707 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical rehabilitation
Number of subjects: 484
Study 30199516 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention, one-on-one telephone-based sessions over 3 months
Number of subjects: 36
Study 30199516 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 36
Study 26769034 — intervention group
Group type: EXPERIMENTAL
Intervention: Parachute
Number of subjects: 50
Study 26769034 — intervention group
Group type: COMPARATOR
Intervention: Control (no parachute)
Number of subjects: 50
Study 25208590 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin intake at bedtime (80 mg)
Number of subjects: 14
Study 25208590 — intervention group
Group type: COMPARATOR
Intervention: Aspirin intake on awakening (80 mg)
Number of subjects: 14
Study 25208590 — intervention group
Group type: EXPERIMENTAL
Intervention: COX‐1‐independent assays
Number of subjects: 14
Study 22995531 — intervention group
Group type: EXPERIMENTAL
Intervention: 220 mg dabigatran etexilate
Number of subjects: 5425
Study 22995531 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg dabigatran etexilate
Number of subjects: 5425
Study 22995531 — intervention group
Group type: COMPARATOR
Intervention: Control group (40 mg enoxaparin)
Number of subjects: 5425
Study 20384537 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical practice improvement studies (PBE)
Number of subjects: 0
Study 20384537 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative research
Number of subjects: 0
Study 20384537 — intervention group
Group type: EXPERIMENTAL
Intervention: Metasynthesis
Number of subjects: 0
Study 17823506 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxamine 50 mg twice daily in PYR-206; escalated to 250 mg twice daily in PYR-205/207
Number of subjects: 212
Study 17823506 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxamine 250 mg twice daily in PYR-205/207
Number of subjects: 212
Study 17823506 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxamine
Number of subjects: 212
Study 17823506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 16044787 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials (RCTs)
Number of subjects: 0
Study 16044787 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 12463460 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg subcutaneously twice weekly
Number of subjects: 60
Study 12463460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12463460 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (in a 6-month open-label extension)
Number of subjects: 60
Study 12463460 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 60
Study 12463460 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (phase 3 trial)
Number of subjects: 60